Moderna Inc. (MRNA)

15.76
0.01 0.06
NASDAQ : Health Technology
Prev Close 15.77
Open 15.90
Day Low/High 15.58 / 16.19
52 Wk Low/High 13.03 / 29.79
Volume 729.16K
Avg Volume 1.14M
Exchange NASDAQ
Shares Outstanding 329.01M
Market Cap 5.07B
EPS -5.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Moderna, Six Flags, Chevron and More: 'Mad Money' Lightning Round

Moderna, Six Flags, Chevron and More: 'Mad Money' Lightning Round

A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.

We're in Bizarro Land: Cramer's 'Mad Money' Recap (Wednesday 6/5/19)

We're in Bizarro Land: Cramer's 'Mad Money' Recap (Wednesday 6/5/19)

Investors should consider recession-proof names in the current environment, Jim Cramer says.

Moderna Announces Presentation Of Interim Data From Phase 1 Study Of MRNA Personalized Cancer Vaccine At 2019 ASCO Annual Meeting

Moderna Announces Presentation Of Interim Data From Phase 1 Study Of MRNA Personalized Cancer Vaccine At 2019 ASCO Annual Meeting

Moderna, Inc., (Nasdaq: MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced interim data from an ongoing Phase 1...

Moderna Announces Publication Of Preclinical Data For Chikungunya Antibody Program

Moderna Announces Publication Of Preclinical Data For Chikungunya Antibody Program

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of preclinical data in...

Moderna Announces Publication Of Phase 1 Data For MRNA Vaccines Against Two Potential Pandemic Influenza Strains

Moderna Announces Publication Of Phase 1 Data For MRNA Vaccines Against Two Potential Pandemic Influenza Strains

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of results from two Phase 1...

Moderna Reports First Quarter 2019 Financial Results And Provides Business Updates

Moderna Reports First Quarter 2019 Financial Results And Provides Business Updates

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results for the first quarter of...

Moderna To Present At Bank Of America Merrill Lynch 2019 Health Care Conference

Moderna To Present At Bank Of America Merrill Lynch 2019 Health Care Conference

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.

Moderna To Present Preclinical Data At 2019 American Society Of Gene & Cell Therapy (ASGCT) Annual Meeting

Moderna To Present Preclinical Data At 2019 American Society Of Gene & Cell Therapy (ASGCT) Annual Meeting

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will present, along with academic...

These Stocks Are Too Hot: Cramer's 'Mad Money' Recap (Thursday 4/18/19)

These Stocks Are Too Hot: Cramer's 'Mad Money' Recap (Thursday 4/18/19)

Cramer says these red-hot and hopelessly overvalued IPOs are signs people are too bullish. Here's your game plan for next week.

Kraft Heinz, PepsiCo, Marvell Technology: 'Mad Money' Lightning Round

Kraft Heinz, PepsiCo, Marvell Technology: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Kraft Heinz, PepsiCo, Marvell Technology, General Mills, Funko, Signet Jewelers, Abiomed and more.

Moderna To Host Science Day On May 7, 2019 And Report First Quarter Financial Results On May 8, 2019

Moderna To Host Science Day On May 7, 2019 And Report First Quarter Financial Results On May 8, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day...

McDonald's, Moderna, Twilio: 'Mad Money' Lightning Round

McDonald's, Moderna, Twilio: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at McDonald's, Moderna, Illinois Tool Works, Twilio and more.

Top-Callers Are Back: Cramer's 'Mad Money' Recap (Tuesday 4/9/19)

Top-Callers Are Back: Cramer's 'Mad Money' Recap (Tuesday 4/9/19)

Jim Cramer says a garden-variety pullback is reasonable, but don't be spooked by pundits and portfolio managers.

Moderna To Present At 18th Annual Needham Healthcare Conference

Moderna To Present At 18th Annual Needham Healthcare Conference

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.

Moderna Reports 2018 Fourth Quarter And Full Year Financial Results And Highlights Recent Pipeline Progress

Moderna Reports 2018 Fourth Quarter And Full Year Financial Results And Highlights Recent Pipeline Progress

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results for the fourth quarter and...

Buy or Sell the News?: Cramer's 'Mad Money' Recap (Monday 3/4/19)

Buy or Sell the News?: Cramer's 'Mad Money' Recap (Monday 3/4/19)

Jim Cramer analyzes what's driving the sellers and looks into this out-of-high-growth-into-value rotation.

Moderna To Present At Upcoming Investor Conferences In March

Moderna To Present At Upcoming Investor Conferences In March

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming...

Moderna To Report Fourth Quarter And Full Year 2018 Financial Results On Wednesday, March 6, 2019

Moderna To Report Fourth Quarter And Full Year 2018 Financial Results On Wednesday, March 6, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call...

Phase 1 Data Published In Nature Communications Show Potential Of MRNA Encoding VEGF-A As A Regenerative Therapeutic

Phase 1 Data Published In Nature Communications Show Potential Of MRNA Encoding VEGF-A As A Regenerative Therapeutic

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of a Phase 1a/b study in...

Moderna's Small Base Could Surprise on the Upside

Moderna's Small Base Could Surprise on the Upside

Prices have moved above the early January high giving us the simple definition of an uptrend.

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

Jim Cramer sees ripple effects of a storm of IPOs, and is worried about the lack of money coming into the market.

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Fitbit, Moderna, Tilray, Exelixis, Maxar Technology, International Paper and more.

Moderna Announces Positive Interim Phase 1 Data For First Combination Vaccine Against The Respiratory Viruses HMPV And PIV3

Moderna Announces Positive Interim Phase 1 Data For First Combination Vaccine Against The Respiratory Viruses HMPV And PIV3

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced topline data from the first planned interim...

Moderna Announces Dosing Of The First Monoclonal Antibody Encoded By MRNA In A Clinical Trial

Moderna Announces Dosing Of The First Monoclonal Antibody Encoded By MRNA In A Clinical Trial

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the dosing of the first subject in a Phase...

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Jim Cramer makes sense of this market action and has your game plan for next week.

Bank of America, Kemet, Boston Beer: 'Mad Money' Lightning Round

Bank of America, Kemet, Boston Beer: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Bank of America, Kemet, Boston Beer, Diageo, Pilgrim's Pride, Tyson Foods, Moderna and more.

Fear of Missing Out Is the Main Driving Force in This Market

Fear of Missing Out Is the Main Driving Force in This Market

Stick to your methodology and don't let worry of underperformance push you to shift your approach.

Newly Published Pre-Clinical Data Show Intratumoral Injections Of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses In Treated And Distal Tumors

Newly Published Pre-Clinical Data Show Intratumoral Injections Of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses In Treated And Distal Tumors

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of pre-clinical data that...